Study Evaluating the Efficacy and Safety of CM336 Injection in the Treatment of Light-Chain Amyloidosis

Who May Qualify: - Voluntary provision of written willing to sign a consent form and ability to comply with protocol requirements. - Age ≥18 years, any gender. - Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2. - Confirmed diagnosis of primary light-chain (AL) amyloidosis. - Relapsed or refractory primary AL amyloidosis. - Measurable hematologic disease at screening (per protocol-defined criteria). - Involvement of ≥1 amyloid-affected organ. - your organs (liver, kidneys, etc.) are working well enough based on blood tests meeting all protocol-specified criteria within 3 days prior to first dose. Who Should NOT Join This Trial: - Current or prior diagnosis of multiple myeloma. - Received anti-AL amyloidosis therapy within protocol-specified timeframe prior to first dose. - Clinically significant cardiovascular or cerebrovascular disease. - Any active or uncontrolled infection meeting protocol-defined criteria. - Any other condition deemed by the Investigator to preclude safe study participation. Always talk to your doctor about whether this trial is right for you.